No Prescription |
 |
 | ||
|
Sulpitac Solian |
|
| ||
No Prescription » Prescription Drugs 15 » Sulpitac Solian Amisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. Buy Sulpitac Solian and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About Sulpitac Solian: Product Type: Prescription Drugs 15 Sulpitac (Solian Soltus Generic Amisulpride) Sulpitac (Solian Soltus Generic Amisulpride) Solian Soltus Generic Amisulpride 100mg 50 Tablets 100mg 100(2 x 50) Tablets 100mg 200(4 x 50) Tablets 200mg 50 Tablets 200mg 100(2 x 50) Tablets 200mg 200(4 x 50) Tablets 50mg 50 Tablets 50mg 100(2 x 50) Tablets 50mg 200(4 x 50) Tablets Solian Soltus Generic Amisulpride Sulpitac
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
